Earnings and Valuation
This table compares Peak Bio and its competitors top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Peak Bio | $370,000.00 | -$12.83 million | -0.33 |
Peak Bio Competitors | $549.20 million | -$36.47 million | -15.63 |
Peak Bio’s competitors have higher revenue, but lower earnings than Peak Bio. Peak Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Peak Bio and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Peak Bio | N/A | N/A | -253.92% |
Peak Bio Competitors | -4,957.16% | -160.29% | -43.10% |
Volatility & Risk
Insider and Institutional Ownership
50.3% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Peak Bio beats its competitors on 6 of the 9 factors compared.
About Peak Bio
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.